SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:prod.swepub.kib.ki.se:153250547"
 

Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:153250547" > COVID-19 in adult a...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005674naa a2201357 4500
001oai:prod.swepub.kib.ki.se:153250547
003SwePub
008240701s2023 | |||||||||||000 ||eng|
024a http://kipublications.ki.se/Default.aspx?queryparsed=id:1532505472 URI
024a https://doi.org/10.3324/haematol.2022.2808472 DOI
040 a (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Marchesi, F4 aut
2451 0a COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)
264 c 2022-05-12
264 1b Ferrata Storti Foundation (Haematologica),c 2023
520 a Patients with acute myeloid leukemia (AML) are at high risk of dying from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients diagnosed with COVID-19 between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the preceding 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died; death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%), whereas in 3.9% of cases the reason was unknown. Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with better survival when AML treatment could be delayed (80%; P<0.001). Overall survival in patients with a diagnosis of COVID-19 between January 2020 and August 2020 was significantly lower than that in patients diagnosed between September 2020 and February 2021 and between March 2021 and September 2021 (39.8% vs. 60% vs. 61.9%, respectively; P=0.006). COVID-19 in AML patients was associated with a high mortality rate and modifications of therapeutic algorithms. The best approach to improve survival was to delay AML treatment, whenever possible.
700a Salmanton-Garcia, J4 aut
700a Emarah, Z4 aut
700a Piukovics, K4 aut
700a Nucci, M4 aut
700a Lopez-Garcia, A4 aut
700a Racil, Z4 aut
700a Farina, F4 aut
700a Popova, M4 aut
700a Zompi, S4 aut
700a Audisio, E4 aut
700a Ledoux, MP4 aut
700a Verga, L4 aut
700a Weinbergerova, B4 aut
700a Szotkovski, T4 aut
700a Da Silva, MG4 aut
700a Fracchiolla, N4 aut
700a De Jonge, N4 aut
700a Collins, G4 aut
700a Marchetti, M4 aut
700a Magliano, G4 aut
700a Garcia-Vidal, C4 aut
700a Biernat, MM4 aut
700a Van Doesum, J4 aut
700a Machado, M4 aut
700a Demirkan, F4 aut
700a Al-Khabori, M4 aut
700a Zak, P4 aut
700a Visek, B4 aut
700a Stoma, I4 aut
700a Mendez, GA4 aut
700a Maertens, J4 aut
700a Khanna, N4 aut
700a Espigado, I4 aut
700a Dragonetti, G4 aut
700a Fianchi, L4 aut
700a Del Principe, MI4 aut
700a Cabirta, A4 aut
700a Ormazabal-Velez, I4 aut
700a Jaksic, O4 aut
700a Buquicchio, C4 aut
700a Bonuomo, V4 aut
700a Batinic, J4 aut
700a Omrani, AS4 aut
700a Lamure, S4 aut
700a Finizio, O4 aut
700a Fernandez, N4 aut
700a Falces-Romero, I4 aut
700a Blennow, Ou Karolinska Institutet4 aut
700a Bergantim, R4 aut
700a Ali, N4 aut
700a Win, S4 aut
700a Van Praet, J4 aut
700a Tisi, MC4 aut
700a Shirinova, A4 aut
700a Schonlein, M4 aut
700a Prattes, J4 aut
700a Piedimonte, M4 aut
700a Petzer, V4 aut
700a Navratil, M4 aut
700a Kulasekararaj, A4 aut
700a Jindra, P4 aut
700a Sramek, J4 aut
700a Glenthoj, A4 aut
700a Fazzi, R4 aut
700a De Ramon-Sanchez, C4 aut
700a Cattaneo, C4 aut
700a Calbacho, M4 aut
700a Bahr, NC4 aut
700a El-Ashwah, S4 aut
700a Cordoba, R4 aut
700a Hanakova, M4 aut
700a Zambrotta, GPM4 aut
700a Zambrotta, G4 aut
700a Sciume, M4 aut
700a Booth, S4 aut
700a Rodrigues, RN4 aut
700a Sacchi, MV4 aut
700a Garcia-Pouton, N4 aut
700a Martin-Gonzalez, JA4 aut
700a Khostelidi, S4 aut
700a Grafe, S4 aut
700a Rahimli, L4 aut
700a Ammatuna, E4 aut
700a Busca, A4 aut
700a Corradini, P4 aut
700a Hoenigl, M4 aut
700a Klimko, N4 aut
700a Koehler, P4 aut
700a Pagliuca, A4 aut
700a Passamonti, F4 aut
700a Cornely, OA4 aut
700a Pagano, L4 aut
710a Karolinska Institutet4 org
773t Haematologicad : Ferrata Storti Foundation (Haematologica)g 108:1, s. 22-33q 108:1<22-33x 1592-8721x 0390-6078
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:153250547
8564 8u https://doi.org/10.3324/haematol.2022.280847

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy